ImmunityBio has announced the commencement of a Phase I trial evaluating its CD19 (t-haNK) cell therapy for the treatment of ...

NICE’s decisions for both drugs are not final and are pending more evidence. Credit: Art_Photo via Shutterstock. On 23 ...

OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the first ...

Germany-based Ottobock SE & Co. KGaA will hold an approximate 10% stake in Onward’s share capital following the investment.

AngioDynamics has teamed up with the University College London Hospital (UCLH) in the UK to launch a prospective registry ...

There are currently no licensed vaccines to treat norovirus, a highly contagious virus that causes sickness and diarrhoea.

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Over the past few days at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, US, the ...

Otsuka has reported positive interim results from its Phase III trial evaluating sibeprenlimab, a treatment for adults with ...

The study will evaluate the company’s Gen-3 Halo headset as an at-home treatment for mild traumatic brain injury.

Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...